2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

5772 Efficacy and safety of velinotamig in patients with relapsed/refractory multiple myeloma:Results of the Phase 2 study

Min Yang, Weijun Fu, MD, PhD2, Jie Ma3, Baijun Fang, PhD4, Yanjuan He5, Wei Yang6, Pengcheng He7, Yingyu Nan8, Chengcheng Fu, MD,PhD9, Jun Wang10, Chunrui Li, MD,PhD11, Bing Chen12, Hongyu Zhang, PhD13, Jian Hou, Prof.14, Wei Wang15, Ying Lu16, Xin Zhou, MD17, Huili Cai18, Yijian Chen19, Chunyan Sun, MD20, Gang An, MD21, Yajie Wang22, Hang Xiang23, Songfu Jiang, MD24, Liangming Ma25, Luqun Wang26, Rong Zhan27, Fei Li, MD, PhD28, Kaiyang Ding29, Lijuan Chen30, Jiao Chen31, Jing Liu32, Guowei Li33, Chunjie Qin34, Shihua Huang35, Zhenyu Li, PharmD36, Chanjuan Shen37, Wei Wang38, Wenming Chen, MD39, Jie Jin, MD40
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China
3 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
4 Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
5 Xiangya Hospital, Central South University, Changsha, China
6 Shengjing Hospital of China Medical University, Shenyang, China
7 The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
8 Chongqing University Cancer Hospital, Chongqing, China
9 The First Affiliated Hospital of Soochow University, Suzhou, China
10 Changde Hospital, Xiangya School of Medicine, Central South University (First People's Hospital of Changde City), Changde, China
11 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
13 Peking University Shenzhen Hospital, Shenzhen, China
14 Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
15 The Second Affiliated Hospital of Harbin Medical University, Harbin, China
16 The Affiliated People's Hospital of Ningbo University, Ningbo, China
17 The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China
18 The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China
19 The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
20 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhna, China
21 Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
22 The First People's Hospital of Yunnan Province, Kunming, China
23 The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
24 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
25 Shanxi Bethune Hospital, Taiyuan, China
26 Qilu Hospital of Shandong University, Jinan, China
27 Fujian Medical University Union Hospital, Fuzhou, China
28 The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
29 Anhui Provincial Cancer Hospital, Hefei, China
30 Jiangsu Province Hospital, Nanjing, China
31 Chengdu Second People’s Hospital, Chengdu, China
32 The Third Xiangya Hospital, Central South University, Changsha, China
33 Huizhou Municipal Central Hospital, Huizhou, China
34 Liuzhou Workers' Hospital, Liuzhou, China
35 Second People's Hospital of Yibin City, Yibin, China
36 The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
37 Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
38 Chongqing Genrix Biopharmaceutical Co., Ltd., Chongqing, China
39 Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
40 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Introduction: Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge. B-cell maturation antigen (BCMA) is predominantly expressed on plasma cells and represents an attractive therapeutic target. Velinotamig (GR1803) is a BCMA×CD3 bispecific antibody that redirects cytotoxic T cells to BCMA-positive myeloma cells. In the phase I monotherapy study, which comprised a dose-escalation phase and a dose-expansion phase, Velinotamig demonstrated a manageable safety profile and remarkable preliminary efficacy in heavily pretreated patients (pts) with RRMM. Based on these findings, a phase II study was conducted to further evaluate the efficacy, safety, and patient-reported outcomes of Velinotamig in Chinese pts with RRMM.

Methods: This prospective, single-arm, open-label, multicenter phase II study (NCT06566547) enrolled pts aged ≥18 years with triple-class exposed RRMM who had received at least 3 prior lines of therapy including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. Velinotamig was administered intravenously with a priming regimen of 10 μg/kg and 30 μg/kg on Cycle 1 Day 1 (C1D1) and C1D4 respectively followed by 180 μg/kg weekly (cycles 1–9) and every 2 weeks (cycle 10 and beyond), in 28-day cycles. The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC) per 2016 International Myeloma Working Group (IMWG) criteria. Secondary endpoints included duration of response (DOR), duration of complete response (DOCR), progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life (EQ-5D).

Results: A total of 116 pts were enrolled and received Velinotamig. The median age was 62.0 years (range 42–79), 60.0% were male, and pts had a median of 4 prior lines of therapy (range 3–8). Among the cohort, 40.87% had extramedullary disease, 85.22% were stratified as high risk according to Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART) 3.0, and 21.74% had ISS stage III disease. At a median follow-up of 14.32 months, 71 patients (61.21%) remained on treatment. The ORR was 79.13%, with 53.04% achieving complete response (CR) or better and 72.17% achieving very good partial response (VGPR) or better. Minimal residual disease (MRD) negativity rate was 64.35%; the MRD-negativity rate among pts with CR or better was 96.72%. Among pts with extramedullary disease, the ORR was 72.34%, with 34.0% achieving CR or better. Median duration of response (mDOR), median progression-free survival (mPFS), and median overall survival (mOS) were not yet reached. The estimated 12-month DOR, PFS, and OS rates were 76.65% (95% CI: 65.64–84.53), 68.82% (95% CI: 58.75–76.91), and 79.45% (95% CI: 70.69–85.85), respectively. For pts achieving CR or better, median duration of complete response (mDOCR) was not reached, and the estimated 12-month DOCR rate was 78.93% (95% CI: 56.57–90.64). Hematologic adverse events (any grade/grade 3/4) included neutropenia (93.10%/75.00%), lymphopenia (75.86%/72.41%), thrombocytopenia (73.28%/27.59%), and anemia (56.90%/19.83%). Common infections (≥20% any grade) were pneumonia (65.52%) and upper respiratory tract infection (41.38%). Grade 5 infections occurred in 10 pts (8.62%). Cytokine release syndrome occurred in 86.21% of pts (0.86% were grade 3, none were grade 4), and there was one case of grade 1 immune effector cell-associated neurotoxicity syndrome. Treatment with Velinotamig injection was associated with sustained improvement in health-related quality of life. The mean EQ-5D utility index was 0.8537 at baseline, and showed a progressive improvement trend from C3D1through subsequent cycles.

Conclusion: Velinotamig exhibited profound and sustained responses with a tolerable safety profile which was aligned with that of other BCMA×CD3 bispecific therapies in heavily pretreated, triple-class exposed pts with RRMM. The observed survival outcomes and improvement in quality of life suggest Velinotamig as a promising therapeutic option for this population.

Min Yang: No relevant conflicts of interest to declare.